Figure 7. Ixazomib in combination with IFN-α results in reduced tumor cell proliferation in BRAF V600E mutant human melanoma cells.

BRAF V600E mutant (A375) and BRAF wild-type (WM1366 and MeWo) human melanoma tumor cells plated at a density of 3 × 10⁴ cells/well in 96 well plates were treated with complete medium supplemented with either 10% dimethyl sulfoxide (control), 5 × 10³ U/mL IFN-α, 35 nM ixazomib or the combination of 35 nM ixazomib plus IFN-α for 48 hours. After incubation methylthiazolyldiphenyl-tetrazolium bromide (MTT) cell proliferation assay was then performed and cell proliferation rates were measured as optical densities (O.D.) at 570 nm. Data represented as mean ± standard error of the mean. Statistical analysis was performed using t-statistics (* = p < 0.05 vs. controls and * with underlying bracket = p < 0.05 for comparisons among groups).